In a retrospective review of 140 patients diagnosed with advanced melanoma, patients with advanced BRAF-mutant melanoma who were treated with first-line immunotherapy showed significantly longer progression-free survival and overall survival (OS) in comparison to patients treated with first-line BRAF/MEK inhibitors. This evidence concerns the gene MAP2K7 and melanoma.